logo
Share SHARE
FONT-SIZE Plus   Neg

Keryx Says Perifosine X-PECT Phase 3 Trial Failed To Meet Primary Goal

Keryx Biopharmaceuticals, Inc. (KERX) said the Phase 3 "X-PECT", or Xeloda + Perifosine Evaluation in Colorectal cancer Treatment, clinical trial evaluating perifosine (KRX-0401) + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer failed to achieve the primary endpoint of improving overall survival versus capecitabine + placebo.

The company noted that 468 patients at sixty-five U.S. sites participated in the study.

Ron Bentsur, Chief Executive Officer of Keryx, stated, "We are all extremely disappointed with the results of the study...We will evaluate whether our Phase 3 study of Perifosine in relapsed/refractory multiple myeloma will continue as planned.

With approximately $31 million in cash as of March 31, 2012, and a well-controlled burn rate, we plan to focus our resources on the pending completion of the Zerenex (ferric citrate) long-term Phase 3 study for end stage renal disease (ESRD) patients with hyperphosphatemia, expected in the fourth quarter of 2012, and the New Drug Application (NDA) filing for Zerenex which will hopefully follow shortly thereafter."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Cable company Altice USA Inc. increased Wednesday the number of shares it will sell in its initial public offering by 37%, raising around $1.9 billion. In the IPO, the company offered 63.94 million shares at a price of $30 per share, higher than the 46.6 million shares announced last month. Republican members of the Federal Communications Commission have taken steps toward repealing Obama-era net neutrality rules, but the results of a new Morning Consult/Politico poll found broad support for the regulations. Sixty-percent of respondents in the survey said they support the net neutrality rules. Music streaming service Spotify is testing a new ad unit called "Sponsored Songs" on its free service, enabling labels to promote songs on playlists for a fee, TechCrunch reported. Instead of appearing as ad banners like the platform's existing ads, labels can pay to have sponsored songs appear on playlists followed by a user, according to the report.
comments powered by Disqus
Follow RTT